Price movement over the last 24 hours
Accenture plc vs Teladoc Health Inc — how do they compare? Accenture plc trades at $139.1 (market cap $86.98B), while Teladoc Health Inc trades at $9.13 (market cap $1.72B). The key difference: Accenture plc is far larger — about 50.6× Teladoc Health Inc's market cap, and Accenture plc pays a 4.59% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| ACN | TDOC | |
|---|---|---|
Market Cap | $86.98B | $1.72B |
Sector | Technology | Health |
52-Week High | $303.33 | $9.52 |
52-Week Low | $124.41 | $4.47 |
Enterprise Value | $85.20B | $2.01B |
Dividend Yield | 4.59% | — |
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $136.96, down 0.28% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company reported strong revenue growth to $69.67B in 2025 with a net margin of 10.66%, supported by strategic AI partnerships announced in June 2026. Valuation ratios appear attractive with a P/E of 10.94 and EV/EBITDA of 6.65, while analyst consensus remains strongly bullish with a $193.92 price target.
The outlook is positive given consistent earnings outperformance, expanding AI-driven consulting partnerships, and solid cash flow generation. Key risks include competitive pressures in consulting services, execution challenges in integrating AI initiatives, and potential macroeconomic headwinds affecting client spending. The stock offers fundamental value with growth catalysts from digital transformation demand.
Teladoc Health (TDOC) trades at $9.52, up 3.48% today, with technical indicators showing bullish momentum despite overbought RSI readings. The company reported Q1 2026 earnings that missed expectations, but revenue remains stable at $2.53 billion for 2025. Recent news highlights expansion through Walmart's platform and ongoing cost-cutting efforts, though BetterHelp segment weakness persists. Analyst consensus is mixed with 33% buy ratings but a price target below current levels at $7.83.
TDOC's recovery story faces headwinds from persistent net losses and negative cash flow, but low P/S ratio of 0.66 offers valuation appeal. Key risks include competitive pressure and execution challenges, while institutional sentiment remains cautious with no sell ratings. The stock's near-term direction hinges on Q2 earnings results and progress toward profitability.
Trailing returns across standard periods
Latest headlines on both assets
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →